Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Cholangiocarcinoma 1

Interventions

Cyclophosphamide 37fludarabine phosphate 32Peripheral Blood Stem Cell Transplantation 30Busulfan 28Tacrolimus 24Antilymphocyte Serum 23Mycophenolic Acid 21Filgrastim 21Radiotherapy 20Methotrexate 19Cyclosporine 19Melphalan 15Methylprednisolone 14Etoposide 14Whole-Body Irradiation 13Cord Blood Stem Cell Transplantation 11Therapeutics 9Psychiatric Rehabilitation 9Flow Cytometry 8sargramostim 7Sirolimus 7Cytarabine 7Alemtuzumab 6Polymerase Chain Reaction 5Granulocyte Colony-Stimulating Factor 5thymoglobulin 4aldesleukin 4Thiotepa 4Specimen Handling 4Early Intervention, Educational 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × axatilimab × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡